Sweden-based Simris Group, a developer of antibody-drug conjugates (ADCs) built on amanitin payloads, has appointed András ...
Shares in Geron, the US commercial-stage hematology company, fell nearly 16% on Wednesday after the firm said it was ...
US biotech BioMarin Pharmaceutical today announced it has entered into an exclusive worldwide license agreement with GC ...
US pharma major Bristol Myers Squibb (NYSE: BMY) reported third-quarter revenue of $13,069 million, up 7% from a year earlier ...
Responding to the UK Labour government’s Budget announcement on Wednesday, Chris Molloy, chief executive of the BioIndustry ...
Even as Torrent Pharmaceuticals is targeting a semaglutide launch in Brazil within six to nine months, signalling its ...
Transpharmation revealed it has acquired OrganoTherapeutics SARL, a Luxemboug-based company specializing in patient-derived ...
German drugmaker Stada said Thursday that the US regulator has approved Lucamzi (ranibizumab-blrz), a biosimilar to Lucentis ...
A drug trial announcement can describe a treatment as reducing risk, meeting its primary endpoint and producing statistically ...
RNA medicines can reduce the production of proteins involved in disease by acting on the messages cells use to make them. Their development has produced treatments for inherited nerve disorders, ...
US drugmaker Merck & Co (NYSE: MRK) reported third-quarter 2026 revenue of $18,085 million, up 5% from a year earlier.
Yesterday, the US Food and drug Administration (FDA) and the Reagan-Udall Foundation for the FDA convened a public meeting to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results